Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

In patients with COPD both with or without heart failure, AF episodes rise around the time patients are hospitalized for ...

The surprise finding hints that anti–acid reflux therapy may provide benefit in COPD, possibly by reducing micro-aspirations, ...

Dupilumab, an injectable interleukin (IL)-4 and IL-13 pathway inhibitor, recently received FDA approval as the first-ever ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Combining Zephyr and Spiration valve therapy benefited patients with COPD and advanced pulmonary emphysema while imparting a ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

Treatment with Ohtuvayre in COPD was linked to improved lung function and other benefits across key patient subgroups in ...

Exacerbations are recognized to be crucial acute events that are associated with increased hospitalization rates and ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Sponsor:  Consultancy Media for Sanofi and Regeneron In the state of Ohio alone, more than 800,000 people are living with COPD. It’s a chronic lung disease that limits air flow and ...

Village Medical and The COPD Foundation today announced a webinar to support patients through Medicare Annual Enrollment ...